“SURGICAL MANAGEMENT OF MAMMARY TUMOUR IN CANINE”

Presented By –

Dr. Manzoor Ahmad bhat

m. v. sc. Scholar

Department of Veterinary Surgery and Radiology

MAMMARY TUMOUR (MT)

Neoplasia which involve mammary gland Most common in bitches, rare in male(1%) MT consist of 50% of all tumours in bitch Malignant or benign 30% to 50% are malignant malignant tumours spread through

lymphatics and blood vessels primarily to regional lymph nodes and lungs

Other metastatic sites include adrenal glands, kidneys, heart and bones

20

/11

/20

10

PATHOLOGICAL ASPECT

Benign tumours are usually fibroadenoma, adenomas or mesenchymal tumours

Most malignant tumours are carcinomas and these tend to spread after surgery

20

/11

/20

10

ETIOLOGY

Unknown

Hormone dependent

Estrogen and progesterone seems to have a role

Estrogen and progesterone receptors are found in 50% malignant and 70% of benign canine MTs

20

/11

/20

10

OHE AND MAMMARY TUMOUR

MT are prevented if OHE is done before 1 year of age

Risk of developing MT is only 0.05% in bitches spayed before 1st estrous

Risk increases to 8% and 26% after 1st and 2nd estrous respectively

No effect of OHE on MT after 2.5years

20

/11

/20

10

CASE HISTORY

Case no. Date: 7/10/10Spp: canineBreed: labradorAge: 10 yearsSex: FemaleColour: fawnWeight: 27 kg

20

/11

/20

10

HISTORY

Hard lump present on abdomen for last 2 months

Fast growing

Non pregnant and non lactating for last 2 years

Engorgement of teats before 6 month

20

/11

/20

10

PHYSICAL FINDINGS

Tumour like growth of about 12cm diameter involving 2nd right teat

Ulcerated growth was firm but easily movable below the skin

All physiological parameters were found to be normal

Right axillary lymph nodes were palpable (slight swollen)

20

/11

/20

10

DIAGNOSIS 20

/11

/20

10

• Based on history and visual observation

Mammary Tumour

TREATMENT

Medicinal management Antiestrogens (tamoxifen @0.4 to 0.8mg/kg/d

PO), antiprogestins or antiprolactins are advocated by some.

Chemotherapy but no particular protocol. Adriamycin and cyclophosphamide combinations are used

Radiation therapy Immunotherapy Surgical excision is the treatment of choice So it was adopted with out any delay

20

/11

/20

10

PREOPERATIVE MANAGEMENT

0.5mg/kg of Pheneramine maleate was given i/m

1ml of dexamethasone s/c

Carbazochrome salicylate 1ml i/m

20

/11

/20

10

PRE ANESTHETICS

Triflupromazine HCL @ 1mg/kg body weight i/v

Atropine sulphate @0.04mg/kg body weight s/c

20

/11

/20

10

PREPARATION OF SURGICAL SITE

Savlon was applied on the intended area and shaving was done liberally to prepare the site

20

/11

/20

10

ANESTHESIA

Thiopentone Na @ 20mg/kg body weight i/v

5% solution was prepared and 1/3rd was sufficient for induction

2/3rd was used for maintenance

Total dose of 300mg was sufficient for the whole surgical procedure to complete successfully

20

/11

/20

10

SURGICAL PROCEDURE 20

/11

/20

10

POST-OPERATIVE THERAPY Antibiotics – ceftriaxone 500 mg i/m for 5

days

NSAID- meloxicam @ 0.5 mg/kg for 5 days

Antihistaminic- pheneramine maleate @ 0.5mg/kg for 4 more days

RL 200ml i/v for 2days

Daily dressing of surgical wound for 5 days.

20

/11

/20

10

20

/11

/20

10